Overview

Pilot Study of RR-HNK in OCD

Status:
NOT_YET_RECRUITING
Trial end date:
2029-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.
Phase:
PHASE1
Details
Lead Sponsor:
Carolyn Rodriguez
Collaborator:
National Institutes of Health (NIH)
Treatments:
6-hydroxynorketamine